Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Commercial Insight: HIV in the USA - Increasing Choice, Flexibility and Competition Datamonitor, June 2003, Pages: 174   Description     Table of Contents        Enquire before Buying    Send to a Friend   With a focus on the commercial environment within the HIV sector in the USA, this Analysis investigates key market characteristics and the strategies required to improve market conditions. Analysis of company portfolio strategies and product positioning provides the reader with knowledge of how company strategies result in varying levels of commercial returns. Scope: - Detailed case studies featuring company portfolio, product development and launch strategies - US sales data for the top 10 HIV products along with forecasts to 2011 for the top 10 selling HIV drugs and classes - Swot analyses of key HIV drugs are provided, along with 12-month event screens - providing detailed knowledge of events specific to each product Report Highlights: Despite a predicted slow down in overall growth and key obstacles with regard to efficacy, diagnosis, resistance and compliance, we predict that the US HIV market will more than double by 2011 providing an additional $4.2 bn in revenue. The approval of Roche’s novel fusion inhibitor Fuzeon will change treatment strategies for late stage patients. The key barrier to use is its delivery method (subcutaneous) and high price. With the launch of BMS’ Reyataz and BI’s tipranavir, the PI drug class will be as large as the Nrti drug class in terms of number of therapeutics. This will shift the usage of Haart towards Nrti-sparing regimens. Reasons to Purchase: - Understand the relationship between company product positioning strategies and HIV market characteristics - Gain insight to HIV portfolio strategies and factors that drive successful drug development and launch Customers who bought this item also bought Commercial Insight: HIV - From the Na�ve to the Complex HIV Update 2003 (1) - January Strategic Perspectives: Opportunistic Infections in HIV HIV Update 2002 (11) - November HIV Update 2003 (3) - March HIV Update 2002 (12) - December HIV Pricing Strategies in the US and UK HIV Update 2003 (2) - February

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster